Eli Lilly and Company

Other

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Lead Discovery Center Gmbh

Bayer Intellectual Property Gmbh

Gerd Ruhter

Robert M Scarborough

Philip Lienau

Gerhard Siemeister

Theo Schotten

Michael Paal

Joseph A Jakubowski

Kenneth James Ruterbories

Daniel Jon Sall

Rolf Bohlmann

Wolfgang Stenzel

Matthew Joseph Fisher

John Joseph Masters

Michael J Martinelli

Dirk Kosemund

Jeffrey Thomas Mullaney

John Michael Morin, Jr

Michael Dean Kinnick

Anne Marie Happ

William F Heath, Jr

Michael R Jirousek

John H McDonald, Iii

Arne Scholz

Kumiko Takeuchi

Mark Jean Gnoth

Robert Theodore Vasileff

Allen D Kline

Michael I Bukrinsky

Uwe Koch

James P Kanter

Peter Nussbaumer

Jan Eickhoff

Barbara S Briggs

Carsten Schultz-Fademrecht

Bert Klebl

Marshall A Skelton

Axel Choidas

Gunter Fischer

Uko Effiong Udodong

John J G Mullins

Stephanie Constant

Milton Zmijewski, Jr

Miroslav Malesevic

Frank Erdmann

Klaus Dinkel

Daniel Verral, Ii

Ulrich Lucking

William Francis Heath Junior Heath

John Hampton Iii Mcdonald

Schotten Theo

The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.

Cyclosporin derivatives

Disclosed are process steps and novel processes for producing chromane compositions enriched in at least one (2R or 2S) enantiomer, preferably chroman-2-yl carboxylic acid compounds and chroman-2-yl carboxylic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors. Further disclosed are enzymatic processes for resolving chiral intermediates or final products to provide desired enantiomers.

Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor

This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation

This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.

Hypoglycemic imidazoline compounds

This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I):

This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Glycoprotein IIB IIIA antagonists

Glycoprotein IIb/IIIa antagonists

The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.

Protein kinase C inhibitors

Growing community of inventors

Hamburg, Germany

Gerd Ruhter